The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The dual SRC-ABL inhibitors in Ph+ acute lymphoblastic leukemia to enhance synergy between targeted BCR-ABL and BCL-2 inhibitors.
 
Jessica Taft Leonard
No Relationships to Disclose
 
Stephen Edward Forbes Spurgeon
No Relationships to Disclose
 
Elie A. Traer
No Relationships to Disclose
 
Brandon M. Hayes-Lattin
No Relationships to Disclose
 
Marc Loriaux
No Relationships to Disclose
 
Jeffrey Tyner
No Relationships to Disclose
 
Brian J. Druker
Stock and Other Ownership Interests - Blueprint Medicines; CTI; Cylene; Lorus; MolecularMD
Honoraria - Agios
Consulting or Advisory Role - Ambit BioSciences; AstraZeneca; Blueprint Medicines; CTI; Cylene; D3 Oncology Solutions; Gilead Sciences; Lorus; MolecularMD; Roche
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Oncotide Pharmaceuticals
Patents, Royalties, Other Intellectual Property - I receive royalties from Dana-Farber Cancer Institute (DFCI), who has an exclusive commercial license with Millipore (formerly Upstate Biotechnology) for monoclonal antiphosphotyrosine antibody 4G10, which I developed while employed at DFCI.; Oregon Health & Science University patents from which I have or will receive royalties as an inventor: o #843 Mutated ABL Kinase Domains (has been licensed to ARIAD Pharmaceuticals, Inc.; Array BioPharma, Inc.; Curis, Inc.; MolecularMD Corporation; Pfiz
Travel, Accommodations, Expenses - Blueprint Medicines; Gilead Sciences
 
Bill H. Chang
No Relationships to Disclose